Financing channel feed – Endpoints News

Financing channel feed

Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world's best-selling vaccine

8 years ago

Manufacturing experts at Hangzhou Just Biotherapeutics bank $35M for stealthy R&D in China and the US

8 years ago

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application

8 years ago

Rich Heyman's Metacrine tacks on another $65M to tackle a superior NASH drug

8 years ago

Pfizer adds $600M to its venture group, with a special focus on the neurosciences field it just retreated from

8 years ago

Clinical trial disruptor Science 37 in talks with SoftBank on a $150M investment — Recode

8 years ago

Hours after filing $150M IPO, Tricida shares positive PhIII trial results on CKD drug

8 years ago

With $1.2B NASH deal behind them, Nimbus raises $65M for I/O, other R&D

8 years ago

Stanford spinout Forty Seven arrives at ASCO with a snapshot of promising CD47 data — and a $115M IPO in hand

8 years ago

Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer treatment

8 years ago

Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights

8 years ago

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai

8 years ago

Eidos, Avrobio shoot for $201M as biotech IPOs continue to roll forward on Nasdaq

8 years ago

Kezar and Xeris file for IPOs, joining May's march to the public markets

8 years ago

Magenta Therapeutics unveils plans to raise $100M in IPO weeks after a crossover round

8 years ago

Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug

8 years ago

Aptinyx looks to bring its NMDA pipeline to Nasdaq, filing for an $80 million IPO

8 years ago

Versant backs new approach to gamma delta T cells, co-leads Lava's $18.9M round

8 years ago

Fighting for a place in the ulcerative colitis market, Sublimity raises $64M for an alternative drug to anti-TNF

8 years ago

Grail hauls in monster $300M round from Chinese investors amid rumors about Hong Kong IPO

8 years ago

Bay Area startup Rain Therapeutics nabs $18M Series A to target lung cancer niche

8 years ago

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead

8 years ago

Tel Aviv VC fund aMoon gets $250M from Credit Suisse, emerges as top player in Israel

8 years ago

His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor

8 years ago

First page Previous page 128 129 130131132 133 134 Next page Last page